About: Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
Creator	Blanco, Francisco Blanco, Ricardo Castrejón, Isabel Fernandez-Fernandez, David Fernandez-Gutierrez, Benjamín Galindo-Izquierdo, María Manrique-Arija, Sara Mena Vázquez, Natalia Mera Varela, Antonio Pablos, Jose Retuerto, Miriam Seijas-Lopez, Alvaro
Source	Medline; PMC
abstract	BACKGROUND: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. METHODS: We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups. RESULTS: Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution. CONCLUSION: Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1136/annrheumdis-2020-217763
bibo:pmid	32532753
has license	no-cc
sha1sum (hex)	3594af922be8b4041f3db4686cca255414a9ecfa
schema:url	https://doi.org/10.1136/annrheumdis-2020-217763
resource representing a document's title	Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
has PubMed Central identifier	PMC7299645
has PubMed identifier	32532753
schema:publication	Ann Rheum Dis
resource representing a document's body	covid:3594af922be8b4041f3db4686cca255414a9ecfa#body_text
is schema:about of	named entity 'autoimmune' named entity 'coVid-19' named entity 'rheumatic diseases' named entity 'spain' named entity 'ICU' named entity 'inflammatory diseases' named entity 'málaga, spain' named entity 'Sjögren's syndrome' named entity 'medical record' named entity 'rheumatic conditions' named entity 'methotrexate' named entity 'medical records' named entity 'spain' named entity 'rheumatology' named entity 'spain' named entity 'rheumatology' named entity 'SARS-CoV-2' named entity 'autoimmune conditions' named entity 'psoriatic arthritis' named entity 'PCR testing' named entity 'inflammatory arthritis' named entity 'COVID' named entity 'Spain' named entity 'SARS-CoV-2' named entity 'palop' named entity 'antirheumatic' named entity 'infectious diseases' named entity 'Behcet's' named entity 'autoimmune' named entity 'IMID' named entity 'madrid' named entity 'coVid-19' named entity 'Rodrigo aguirre' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Universidad complutense' named entity 'Rheumatic Diseases' named entity 'rheumatic diseases' named entity 'rheumatic diseases' named entity 'Julio Ramírez' named entity 'IMID' named entity 'autoimmune' named entity 'autoimmune' named entity 'spain' named entity 'disease-modifying antirheumatic drug' named entity 'rheumatoid arthritis' named entity 'clinical practice' named entity 'COVID-19' named entity 'COVID' named entity 'risk factors' named entity 'Median age' named entity 'COVID' named entity 'giant cell arteritis' named entity 'age distribution' named entity 'spondyloarthritis' named entity 'disease-modifying antirheumatic drug' named entity 'IMID' named entity 'infection' named entity 'systemic sclerosis' named entity 'chronic inflammatory diseases' named entity 'madrid' named entity 'spain' named entity 'madrid' named entity 'santander, spain' named entity 'follow-up' named entity 'infection' named entity 'SARS-CoV-2' named entity 'infection' named entity 'chimeric antigen receptor' named entity 'spain' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software